[The value of urine cystein proteinase and serum CA125 measurement in monitoring the treatment of malignant ovarian tumor].
Urine cystein proteinase (UCP) and serum CA125 were measured in 40 patients with malignant ovarian tumor (malignant group), 40 patients with benign ovarian tumor (benign group), and 40 normal control (normal group). 28 patients in the malignant group underwent UCP and CA125 measurement pre-operation, post-operation, and during three courses of chemotherapy. The enzyme activity of UCP in the malignant group was significantly higher than that in the benign and normal groups (P < 0.05 or 0.01). The values of UCP in patients with malignant tumor of stages II-IV were significantly higher compared with those of stages I-II (P < 0.01, 0.05). The activity of UCP was elevated pre-operation, post-operation, and was much higher on the seventh day postoperation. After the seventh day, UCP activity decreased gradually. Serum CA125 was also detected pre-operation, at 7.30 and 60 days post-operation. The levels of UCP and CA125 pre-operation and 30, 60 days post-operation in the patients whose residual carcinoma lesions were > 2 cm in diameter were apparantly higher than those with no residual lesions (P < 0.05). UCP and CA125 values were measured in six patients before relaparotomy. The sensitivity, specificity, accuaracy, positive predictive value and negative predictive value for UCP assay are 980%, 100%, 83%, 100% and 50% and those for CA125 assay are 40%, 100%, 80%, 100%, and 25%, respectively.